The finding of CHM efficacy as an adjunctive therapy for breast cancer is similar to the findings of other reviews for hepatocellular carcinoma, non-small-cell lung cancer, colorectal cancer, and nasopharyngeal carcinoma [58, 64–66]. The gene discussed is CHM; the disease is colorectal cancer.